A randomized controlled trial is assessing the safety and effectiveness of levofloxacin in reducing infection risk in MDS and AML patients undergoing outpatient chemotherapy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— levofloxacin

Monitor the trial's progress and results, particularly the feasibility outcomes and any plans for a subsequent phase 3 trial.

June 30, 2026 · N/A

Indications

Myelodysplastic Syndromes and Acute Myeloid Leukemia →

Therapeutic areas

Hematology →

Hematology · Myelodysplastic Syndromes and Acute Myeloid Leukemia →

Myelodysplastic Syndromes and Acute Myeloid Leukemia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.